Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, Navis G.

Curr Vasc Pharmacol. 2011 Sep;9(5):594-605. Review.

PMID:
21529330
[PubMed - indexed for MEDLINE]
2.

Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?

Mansur SJ, Hage FG, Oparil S.

Curr Cardiol Rep. 2010 Nov;12(6):450-63. doi: 10.1007/s11886-010-0140-7. Review.

PMID:
20827517
[PubMed - indexed for MEDLINE]
3.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
[PubMed - indexed for MEDLINE]
4.

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.

Alfie J, Aparicio LS, Waisman GD.

Rev Recent Clin Trials. 2011 May;6(2):134-46. Review.

PMID:
21241234
[PubMed - indexed for MEDLINE]
5.

Effect of aldosterone and MR blockade on the brain and the kidney.

Stier CT Jr, Rocha R, Chander PN.

Heart Fail Rev. 2005 Jan;10(1):53-62. Review.

PMID:
15947892
[PubMed - indexed for MEDLINE]
6.

Aldosterone and end-organ damage.

Marney AM, Brown NJ.

Clin Sci (Lond). 2007 Sep;113(6):267-78. Review.

PMID:
17683282
[PubMed - indexed for MEDLINE]
Free Article
7.

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Remuzzi G, Perico N, Macia M, Ruggenenti P.

Kidney Int Suppl. 2005 Dec;(99):S57-65. Review.

PMID:
16336578
[PubMed - indexed for MEDLINE]
Free Article
8.

Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.

Lu Y, Ku E, Campese VM.

Curr Hypertens Rep. 2010 Aug;12(4):303-6. doi: 10.1007/s11906-010-0116-4. Review.

PMID:
20596805
[PubMed - indexed for MEDLINE]
9.

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

Bertocchio JP, Warnock DG, Jaisser F.

Kidney Int. 2011 May;79(10):1051-60. doi: 10.1038/ki.2011.48. Epub 2011 Mar 16. Review.

PMID:
21412221
[PubMed - indexed for MEDLINE]
10.

Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.

Joffe HV, Adler GK.

Heart Fail Rev. 2005 Jan;10(1):31-7. Review.

PMID:
15947889
[PubMed - indexed for MEDLINE]
11.

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.

Bomback AS, Toto R.

Am J Hypertens. 2009 Oct;22(10):1032-40. doi: 10.1038/ajh.2009.138. Epub 2009 Aug 6. Review.

PMID:
19661925
[PubMed - indexed for MEDLINE]
12.

Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.

Zannad F, Radauceanu A.

Heart Fail Rev. 2005 Jan;10(1):71-8. Review.

PMID:
15947894
[PubMed - indexed for MEDLINE]
13.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
[PubMed - indexed for MEDLINE]
14.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D.

J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. Review.

PMID:
19727007
[PubMed - indexed for MEDLINE]
15.

Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Ku E, Campese VM.

Pediatr Nephrol. 2009 Dec;24(12):2301-7. doi: 10.1007/s00467-009-1176-z. Epub 2009 Apr 4. Review.

PMID:
19347366
[PubMed - indexed for MEDLINE]
17.

Mineralocorticoid receptor activation in obesity hypertension.

Nagase M, Fujita T.

Hypertens Res. 2009 Aug;32(8):649-57. doi: 10.1038/hr.2009.86. Epub 2009 Jun 12. Review.

PMID:
19521418
[PubMed - indexed for MEDLINE]
18.

The endothelin-aldosterone axis and cardiovascular diseases.

Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC.

J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S49-52.

PMID:
11811378
[PubMed - indexed for MEDLINE]
19.

Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.

Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giacchetti G.

Curr Vasc Pharmacol. 2012 Mar;10(2):238-46. Review.

PMID:
22022770
[PubMed - indexed for MEDLINE]
20.

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

Rao MS.

J Assoc Physicians India. 2010 Feb;58:102-8. Review.

PMID:
20653151
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk